Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
J Pharmacol Sci ; 148(4): 364-368, 2022 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-35300811

RESUMEN

We examined whether galantamine (GAL), a cholinesterase inhibitor and allosteric potentiating ligand for α7 nicotinic acetylcholine receptor (nAChR), had an impact on emotional abnormalities in forebrain-specific cholecystokinin receptor-2 overexpressed transgenic mice. Treatment with GAL (1 mg/kg, s.c.) attenuated the decrease of social interaction time, but failed to attenuate anxiety-like behavior in the elevated plus-maze test. The effect of GAL was blocked by an α7 nAChR antagonist, methyllycaconitine (3 mg/kg, i.p.). These results suggest that GAL improved social interaction impairments via α7 nAChR and could be useful to treat sociability-related emotional abnormalities.


Asunto(s)
Inhibidores de la Colinesterasa , Galantamina , Receptor de Colecistoquinina B , Trastorno de la Conducta Social , Interacción Social , Receptor Nicotínico de Acetilcolina alfa 7/antagonistas & inhibidores , Animales , Inhibidores de la Colinesterasa/farmacología , Inhibidores de la Colinesterasa/uso terapéutico , Galantamina/farmacología , Galantamina/uso terapéutico , Ratones , Receptor de Colecistoquinina B/genética , Receptor de Colecistoquinina B/metabolismo , Trastorno de la Conducta Social/tratamiento farmacológico , Interacción Social/efectos de los fármacos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...